Drug Profile
MK 7622
Alternative Names: MK-7622Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class 3-ring heterocyclic compounds; Antidementias; Pyridines; Quinazolinones; Small molecules
- Mechanism of Action Muscarinic M1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 07 Dec 2018 Discontinued - Phase-II for Alzheimer's disease (Adjunctive treatment) in Canada, USA (PO)
- 18 Apr 2016 Merck terminates a phase IIa/IIb trial for Alzheimer's disease (Adjunctive treatment) in USA and Canada (NCT01852110)
- 24 Dec 2015 MK 7622 is still in phase II trials for Alzheimer's disease (Adjunctive treatment) in USA